




PHARMACEUTICAL 2018

DURECT CORP
Rank 91 of 342





PHARMACEUTICAL 2018

DURECT CORP
Rank 91 of 342



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 107% points. The greatest weakness of DURECT CORP is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 130% points above the market average of 46%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 45,358 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 6,399 |
| Liabilities, Current | 15,828 |
| Liabilities, Non-Current | 0 |
| Other Assets | 427 |
| Other Compr. Net Income | 2.0 |
| Other Expenses | 6,633 |
| Other Liabilities | 0 |
| Other Net Income | -1,458 |
| Other Revenues | 49,170 |
| Property and Equipment | 929 |
| Research and Development | 31,609 |
| Selling, General and Administrative Expense | 13,165 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 53,113 |
| Liabilities | 15,828 |
| Expenses | 51,407 |
| Revenues | 49,170 |
| Stockholders Equity | 37,285 |
| Net Income | -3,695 |
| Comprehensive Net Income | -3,694 |
| Economic Capital Ratio | 175% |